Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

  • ID: 3946398
  • Report
  • 250 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BerGenBio AS
  • Clovis Oncology, Inc.
  • FibroGen, Inc.
  • Incuron, LLC
  • MedImmune, LLC
  • Oryx GmbH & Co. KG
  • MORE
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016, provides an overview of the Pancreatic Ductal Adenocarcinoma (Oncology) pipeline landscape.

Pancreatic ductal adenocarcinoma is a malignant neoplasm that affects pancreas. Symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression, blood clots. Predisposing factors include smoking, alcohol abuse, obesity, family history, age, chronic pancreatitis and diabetes. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 15, 1 and 15 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Ductal Adenocarcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Ductal Adenocarcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BerGenBio AS
  • Clovis Oncology, Inc.
  • FibroGen, Inc.
  • Incuron, LLC
  • MedImmune, LLC
  • Oryx GmbH & Co. KG
  • MORE
Introduction

Pancreatic Ductal Adenocarcinoma Overview

Therapeutics Development

Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies

Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes

Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance

Pancreatic Ductal Adenocarcinoma - Products under Development by Companies

Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes

Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development

Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment

Drug Profiles

Pancreatic Ductal Adenocarcinoma - Dormant Projects

Pancreatic Ductal Adenocarcinoma - Discontinued Products

Pancreatic Ductal Adenocarcinoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016

Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by BerGenBio AS, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by BioNTech AG, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Celgene Corporation, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by COARE Biotechnology, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Concordia International Corp, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Eli Lilly and Company, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Halozyme Therapeutics, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Immodulon Therapeutics Ltd., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Incyte Corporation, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Inflection Biosciences Limited, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by InvivoGen Therapeutics, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by MedImmune, LLC, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Novartis AG, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Oryx GmbH & Co. KG, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Pfizer Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Quest PharmaTech Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Soricimed Biopharma Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Sun BioPharma, Inc., H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Swedish Orphan Biovitrum AB, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016

Pancreatic Ductal Adenocarcinoma - Pipeline by Tokai Pharmaceuticals, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pancreatic Ductal Adenocarcinoma - Dormant Projects, H2 2016

Pancreatic Ductal Adenocarcinoma - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H2 2016

Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
BerGenBio AS
BioNTech AG
Celgene Corporation
Clovis Oncology, Inc.
COARE Biotechnology, Inc.
Concordia International Corp
Eli Lilly and Company
FibroGen, Inc.
Gilead Sciences, Inc.
Halozyme Therapeutics, Inc.
Immodulon Therapeutics Ltd.
Immunomedics, Inc.
Incuron, LLC
Incyte Corporation
Inflection Biosciences Limited
Inovio Pharmaceuticals, Inc.
InvivoGen Therapeutics
MedImmune, LLC
Medisyn Technologies, Inc.
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Oryx GmbH & Co. KG
Pfizer Inc.
Quest PharmaTech Inc.
Sillajen Biotherapeutics
Soricimed Biopharma Inc.
Sun BioPharma, Inc.
Swedish Orphan Biovitrum AB
Tara Immuno-Oncology Therapeutics LLC
Tokai Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll